Considering the interaction between BDNF and oxidative stress in schizophrenia, and the association of oxidative stress with positive, negative and cognitive symptoms, they suggested that antipsychotic-galantamine-memantine combination may provide a novel strategy in schizophrenia to treat positive, negative and cognitive symptoms. The gene discussed is BDNF; the disease is schizophrenia.